Trevi Therapeutics Inc (TRVI)

NASD · Healthcare · Biotechnology · USA

Trevi Therapeutics Inc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio, an oral nalbuphine formulation, to treat chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. The medication targets opioid receptors in the nervous system to suppress cough. The company holds worldwide commercial rights to Haduvio.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Trevi Therapeutics Inc stock.

Our verdict on TRVI

Not valued: We cannot value this company yet.

ETFs with the most weight in TRVI

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than TRVI in Biotechnology

129 more in this industry show a wider margin of safety.

Is TRVI undervalued or overvalued?

We do not publish a verdict on TRVI yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of TRVI?

We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.